Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET3D: DAA Therapy for Recent HCV
NCT02634008Phase 3Completed
- Sponsor
- The Kirby Institute
- Start
- Jun 2016
- Primary completion
- Apr 2021
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of paritaprevir, ritonavir, ombitasvir, dasabuvir, glecaprevir in hepatitis C virus infection, sponsored by The Kirby Institute. Started Jun 2016; status: completed.
02
Drugs
paritaprevirritonavirombitasvirdasabuvirglecaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02634008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02634008.